1887

Abstract

Possible human infection with simian virus 40 (SV40) has been of great concern ever since SV40 was discovered in polio vaccines. Human populations are SV40-seropositive, but because of serological cross-reactivity between SV40 and the human polyomaviruses BK virus (BKV) and JC virus (JCV), it is debatable whether these antibodies are specific. An SV40-specific serological assay was established, based on purified virus-like particles (VLPs), where the SV40 VLPs were blocked with hyperimmune sera to BKV and JCV. Competition with SV40 hyperimmune sera was used as a confirmatory test. Among 288 Swedish children of between 1 and 13 years of age, 7·6 % had SV40-specific antibodies. SV40 seroprevalence reached a peak of 14 % at 7–9 years of age. Among 100 control patients with benign tumours, 9 % were SV40-seropositive. However, SV40 DNA was not detectable in corresponding buffy-coat samples. In serial samples taken up to 5 years apart from 141 Finnish women participating in the population-based serological screening for congenital infections, only two of 141 women were SV40-seropositive in both samples. Six women seroconverted and eight women had a loss of antibodies over time. None of the SV40-seropositive samples contained detectable SV40 DNA. In conclusion, there is a low prevalence of SV40-specific antibodies in the Nordic population. The SV40 antibodies appear to have a low stability over time and their origin is not clear.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80783-0
2005-06-01
2020-08-04
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/6/vir861703.html?itemId=/content/journal/jgv/10.1099/vir.0.80783-0&mimeType=html&fmt=ahah

References

  1. af Geijersstam V., Kibur M., Wang Z., Koskela P., Pukkala E., Schiller J., Lehtinen M., Dillner J. 1998; Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 177:1710–1714 [CrossRef]
    [Google Scholar]
  2. af Geijersstam V., Eklund C., Wang Z., Sapp M., Schiller J. T., Dillner J., Dillner L. 1999; A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children. Int J Cancer 80:489–493 [CrossRef]
    [Google Scholar]
  3. Bergsagel D. J., Finegold M. J., Butel J. S., Kupsky W. J., Garcea R. L. 1992; DNA sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors of childhood. N Engl J Med 326:988–993 [CrossRef]
    [Google Scholar]
  4. Butel J. S., Lednicky J. A. 1999; Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst 91:119–134 [CrossRef]
    [Google Scholar]
  5. Carter J. J., Madeleine M. M., Wipf G. C., Garcea R. L., Pipkin P. A., Minor P. D., Galloway D. A. 2003; Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst 95:1522–1530 [CrossRef]
    [Google Scholar]
  6. Christensen N. D., Reed C. A., Cladel N. M., Han R., Kreider J. W. 1996; Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70:960–965
    [Google Scholar]
  7. Dillner L., Heino P., Moreno-Lopez J., Dillner J. 1991; Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses. J Virol 65:6862–6871
    [Google Scholar]
  8. Engels E. A., Viscidi R. P., Galloway D. A. 8 other authors 2004; Case-control study of simian virus 40 and non-Hodgkin lymphoma in the United States. J Natl Cancer Inst 96:1368–1374 [CrossRef]
    [Google Scholar]
  9. Gedvilaite A., Frommel C., Sasnauskas K. 7 other authors 2000; Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. Virology 273:21–35 [CrossRef]
    [Google Scholar]
  10. Heid C. A., Stevens J., Livak K. J., Williams P. M. 1996; Real time quantitative PCR. Genome Res 6:986–994 [CrossRef]
    [Google Scholar]
  11. Hilleman M. R. 1998; Discovery of simian virus 40 (SV40) and its relationship to poliomyelitis virus vaccines. Dev Biol Stand 94:183–190
    [Google Scholar]
  12. Knowles W. A., Pipkin P., Andrews N., Vyse A., Minor P., Brown D. W. G., Miller E. 2003; Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71:115–123 [CrossRef]
    [Google Scholar]
  13. Minor P., Pipkin P., Jarzebek Z., Knowles W. 2003; Studies of neutralising antibodies to SV40 in human sera. J Med Virol 70:490–495 [CrossRef]
    [Google Scholar]
  14. Olin P., Giesecke J. 1998; Potential exposure to SV40 in polio vaccines used in Sweden during 1957: no impact on cancer incidence rates 1960 to 1993. Dev Biol Stand 94:227–233
    [Google Scholar]
  15. Rector A., Tachezy R., Van Ranst M. 2004; A sequence-independent strategy for detection and cloning of circular DNA virus genomes by using multiply primed rolling-circle amplification. J Virol 78:4993–4998 [CrossRef]
    [Google Scholar]
  16. Sasnauskas K., Buzaite O., Vogel F., Jandrig B., Razanskas R., Staniulis J., Scherneck S., Kruger D. H., Ulrich R. 1999; Yeast cells allow high-level expression and formation of polyomavirus-like particles. Biol Chem 380:381–386
    [Google Scholar]
  17. Shah K. V. 2000; Does SV40 infection contribute to the development of human cancers?. Rev Med Virol 10:31–43 [CrossRef]
    [Google Scholar]
  18. Stolt A., Sasnauskas K., Koskela P., Lehtinen M., Dillner J. 2003; Seroepidemiology of the human polyomaviruses. J Gen Virol 84:1499–1504 [CrossRef]
    [Google Scholar]
  19. Stolt A., Kjellin M., Sasnauskas K., Luostarinen T., Koskela P., Lehtinen M., Dillner J. 2005; Maternal human polyomavirus infection and risk of neuroblastoma in the child. Int J Cancer 113:393–396 [CrossRef]
    [Google Scholar]
  20. Strickler H. D., Goedert J. J. 1998; Exposure to SV40-contaminated poliovirus vaccine and the risk of cancer – a review of the epidemiological evidence. Dev Biol Stand 94:235–244
    [Google Scholar]
  21. Sweet B. H., Hilleman M. R. 1960; The vacuolating virus, S.V. 40. Proc Soc Exp Biol Med 105:420–427 [CrossRef]
    [Google Scholar]
  22. Tedeschi R., Enbom M., Bidoli E., Linde A., De Paoli P., Dillner J. 2001; Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol 39:4269–4273 [CrossRef]
    [Google Scholar]
  23. Vilchez R. A., Kozinetz C. A., Butel J. S. 2003; Conventional epidemiology and the link between SV40 and human cancers. Lancet Oncol 4:188–191 [CrossRef]
    [Google Scholar]
  24. Viscidi R. P., Rollison D. E. M., Viscidi E., Clayman B., Rubalcaba E., Daniel R., Major E. O., Shah K. V. 2003; Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol 10:278–285
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80783-0
Loading
/content/journal/jgv/10.1099/vir.0.80783-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error